Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures
NCT ID: NCT02220387
Last Updated: 2015-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
352 participants
OBSERVATIONAL
2014-08-31
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures 2
NCT02284295
Air Pollution and Health of COPD Patients
NCT05076630
Markers for Chronic Obstructive Pulmonary Disease (COPD)
NCT00180622
Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
NCT02346292
COPD Originates in Polluted Air
NCT02236039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Occupational factors leading airflow limitation are various entities - vapors, dusts, gases and fumes with different physical, chemical, biological and other features, so the mechanisms underlying disease development and progression may be different attributable to risk factor.
An environmental risk factors exposure as well as tobacco smoking results in COPD only in part of the subjects which indicates the significant genome and gene environmental interactions role. COPD develops in predisposed subjects undergoing risk factors exposure. Therefore the risk of COPD is individual and depends on both genetic and environments. There are few data concerning the effects of genetic on COPD risk in this specific subgroup - people who are exposed to occupational risk factors related to the certain environmental factor.
Statistical analysis: Statistical analysis will be carried out by Statistica 9.0 software. Significance level will be considered p = 0.05. The qualitative variables will be expressed as counts and percentages. The quantitative continuous variables will be expressed as means and standard error of means (M ± m) for variables that meet the criteria of normality and minimum and maximum, median for those that do not meet the criteria of normality. Kruskal-Wallis test will be used for comparing multiply independent samples and Mann-Whitney U test for comparing two independent samples if variable under consideration will continuous and that it will be measured on an ordinal scale. For comparisons of proportions, the Chi-square will be used.
For associations assessment logistic regression method will be used. The odds ratio (OR) and 95% confidence interval (CI) will be calculated for each professional group. Multiple regression model will be used to explore the relationships between demographic characteristics, cytokine concentrations, hemostasis and airflow limitation in professional groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
occupational COPD
Consists of 2 subgroups
1. COPD patients with history of exposure to respirable silica dust
2. COPD patients with history of exposure to polycyclic aromatic hydrocarbons exhaust
exposure to respirable silica dust
History of exposure to respirable silica dust due to job
exposure to polycyclic aromatic hydrocarbons exhaust
history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
smokers with COPD and healthy control
Consists of 2 subgroups
1. patients with COPD, history of tobacco smoke and no history of occupational exposure
2. healthy subjects
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
exposure to respirable silica dust
History of exposure to respirable silica dust due to job
exposure to polycyclic aromatic hydrocarbons exhaust
history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable phase of COPD
* History of exposure to respirable silica dust, nonsmokers with absence of passive exposure to tobacco smoke or history of exposure to polycyclic aromatic hydrocarbons exhaust, nonsmokers with absence of passive exposure to tobacco smoke or current tobacco smokers without history of occupational exposure
* COPD risk factor exposure (occupational or tobacco smoke) duration not less than 12 months
* Male
* Caucasian
* Age of 40 - 75 years old
* Control group - healthy people
Exclusion Criteria
* age less than 40 and above 75 years old
* current COPD exacerbation
* concomitant asthma
* tuberculosis and other pulmonary diseases
* allergic and autoimmune disorders
* active infections
* immunodeficiency, including HIV infection
* parasitological diseases
* malignancies
* lack of informed consent
40 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Siberian Branch of the Russian Academy of Medical Sciences
OTHER
Novosibirsk City Hospital #2
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Liubov A Shpagina
Prof., Dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Liubov Shpagina, PhD
Role: PRINCIPAL_INVESTIGATOR
Novosibirsk Citi Hospital #2, Novosibirsk State Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novosibirsk City Hospital #2
Novosibirsk, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01201463369
Identifier Type: OTHER
Identifier Source: secondary_id
01201463369/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.